Start Date
31-10-2023 12:00 PM
End Date
31-10-2023 2:00 PM
Description
We utilized a novel explainable artificial intelligence (XAI) approach to identify Interleukin-27 Receptor α (IL-27Rα) as a potential therapeutic target for high grade serous ovarian cancer (HGSC) patients based on the Cancer Genome Atlas (TCGA) dataset. High expression of IL-27Rα was found to be significantly correlated with poorer survival in HGSC patients. To investigate its therapeutic potential, we silenced IL-27Rα in murine HGSC cells lines using siRNA and assessed its impact on tumor proliferation, migration, invasion, and angiogenesis. Our results demonstrated that IL-27Rα siRNA effectively reduced its expression, as confirmed by Western Blot analysis, and significantly attenuated proliferation by clonogenic assay, migration by wound healing assay, and invasion assay, and angiogenesis by tube formation. These findings support the potential of targeting IL-27Rα as a promising strategy for improving outcomes in HGSC
Included in
MD Anderson Internship: Targeting IL-27Rα in Ovarian Cancer
We utilized a novel explainable artificial intelligence (XAI) approach to identify Interleukin-27 Receptor α (IL-27Rα) as a potential therapeutic target for high grade serous ovarian cancer (HGSC) patients based on the Cancer Genome Atlas (TCGA) dataset. High expression of IL-27Rα was found to be significantly correlated with poorer survival in HGSC patients. To investigate its therapeutic potential, we silenced IL-27Rα in murine HGSC cells lines using siRNA and assessed its impact on tumor proliferation, migration, invasion, and angiogenesis. Our results demonstrated that IL-27Rα siRNA effectively reduced its expression, as confirmed by Western Blot analysis, and significantly attenuated proliferation by clonogenic assay, migration by wound healing assay, and invasion assay, and angiogenesis by tube formation. These findings support the potential of targeting IL-27Rα as a promising strategy for improving outcomes in HGSC